A Phase 3 interventional study of FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids and FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The efficacy and safety of FTY720 is being evaluated in patients who receive a kidney transplant.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Drug: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Drug: MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Drug page: Fingolimod
FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Drug page: Fingolimod
FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Drug page: Mycophenolic Acid
mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
IA, IB, IIA, IIB, III, or humoral rejection diagnosed by biopsy according to Banff 97 criteria within 12 months post transplant
permanent resumption of dialysis within 12 months post transplant
surgical removal of graft within 12 months post transplant
death within 12 months post transplant
withdrawal of consent, death, or lost to follow up within 12 months post transplant
FEV1 , FVC, FEV1/FVC, DLCO and FEF 25%-75% at day 28, months 6 and 12
serum creatinine
cystatin C at months 3, 6, and 12
proteinuria at day 28, months 6 and 12
absolute lymphocyte count at screening, baseline, day 1, 7, 14, and 28, months 2, 3, 6, 9, and 12
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
The record gives a start of May 2003, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fingolimod · Mycophenolic Acid
Rejection, Psychology